GSK and Vir's Sotrovimab Meet its Primary Endpoints in P-III COMET-TAIL Trial for the Treatment of COVID-19
Shots:
- The P-III COMET-TAIL trial evaluates the efficacy, safety & tolerability of sotrovimab (250/500mg, given as IM compared to IV) in 983 high-risk patients aged =12yrs. with COVID-19 for 7 days after symptom onset. This trial is based on the results of a P-III COMET-ICE trial
- The trial meet its 1EPs i.e, sotrovimab (IM) was non-inferior & offered similar efficacy to IV administration for high-risk populations, 2.7% rate of progression to hospitalization for 24+ hrs. or death @29 days vs 1.3% in the IV administration in 500mg dose
- The companies plan for regulatory submissions globally in Q1'22 including ongoing FDA discussions. Sotrovimab is an investigational SARS-CoV-2 neutralizing mAb
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com